Cytosorbents News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.05.22	CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook (PR Newswire)
02.05.22	CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany (PR Newswire)
02.05.22	Ausblick: Cytosorbents mit Zahlen zum abgelaufenen Quartal (finanzen.net)
29.04.22	First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery (PR Newswire)
28.04.22	CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress (PR Newswire)
19.04.22	CytoSorbents to Report First Quarter 2022 Operating and Financial Results (PR Newswire)
14.04.22	CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World (PR Newswire)
07.04.22	CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program (PR Newswire)
05.04.22	CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors (PR Newswire)
17.03.22	CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM) (PR Newswire)
08.03.22	CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook (PR Newswire)
08.02.22	CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results (PR Newswire)
03.02.22	CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences (PR Newswire)
01.02.22	First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock (PR Newswire)
24.01.22	New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology (PR Newswire)
18.01.22	CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue (PR Newswire)
21.12.21	CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular (PR Newswire)
20.12.21	CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) (PR Newswire)
15.11.21	CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference (PR Newswire)
04.11.21	CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results (PR Newswire)
03.11.21	Ausblick: Cytosorbents legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
20.10.21	CTSO : No Signal For Harm On CytoSorb Use In Patients Undergoing Surgery For Infective Endocarditis (RTTNews)
20.10.21	CytoSorbents Comments on REMOVE Study Presentation (PR Newswire)
20.10.21	Erste Schätzungen: Cytosorbents mit Zahlen zum abgelaufenen Quartal (finanzen.net)
14.10.21	First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery (PR Newswire)
13.10.21	Pre-market Movers: WTRH, NEW, RGLS, KOSS, PROC… (RTTNews)
12.10.21	CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System Dur... (PR Newswire)
12.10.21	CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance (PR Newswire)
07.10.21	CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference (PR Newswire)
14.09.21	CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19 (PR Newswire)
13.09.21	CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies (PR Newswire)
10.09.21	CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During... (PR Newswire)
08.09.21	CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) (PR Newswire)
01.09.21	U.S. CTC Registry Shows High Survival Using CytoSorb In Critically Ill COVID-19 Patients On ECMO (RTTNews)
01.09.21	Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) (PR Newswire)
30.08.21	CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress (PR Newswire)
12.08.21	Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent C... (PR Newswire)
03.08.21	CytoSorbents Reports Second Quarter 2021 Financial and Operational Results (PR Newswire)
01.08.21	Ausblick: Cytosorbents präsentiert Quartalsergebnisse (finanzen.net)
30.07.21	CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE (PR Newswire)
20.07.21	Erste Schätzungen: Cytosorbents legt Quartalsergebnis vor (finanzen.net)
19.07.21	CytoSorbents to Report Second Quarter 2021 Operating and Financial Results (PR Newswire)
06.07.21	CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery (PR Newswire)
02.05.21	Ausblick: Cytosorbents präsentiert Quartalsergebnisse (finanzen.net)
07.03.21	Ausblick: Cytosorbents legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
22.02.21	Erste Schätzungen: Cytosorbents zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
04.01.21	CytoSorbents : Health Canada Okays CytoSorb For Use In Hospitalized COVID-19 Patients (RTTNews)
03.11.20	Ausblick: Cytosorbents zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
30.09.20	So schätzen die Analysten die Cytosorbents-Aktie im September 2020 ein (finanzen.net)
03.08.20	Ausblick: Cytosorbents präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Cytosorbents Corp

Aktien Top/Flop

Meistgelesene Nachrichten